表紙
市場調查報告書

細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13):開發中產品分析

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 358696
出版日期 內容資訊 英文 134 Pages
訂單完成後即時交付
價格
Back to Top
細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13):開發中產品分析 Cellular Tumor Antigen p53 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 134 Pages
簡介

本報告提供全球各國治療細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要的疾病及藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 細胞性腫瘤抗體P53 (腫瘤抑制劑P53/抗體NY-CO-13)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 臨床實驗後期階段的產品
    • 臨床實驗初期階段的產品
  • 各企業開發中的產品
  • 各大學/研究機關開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • 細胞性腫瘤抗體P53 (腫瘤抑制劑P53/抗體NY-CO-13) 治療藥的開發企業
    • Advaxis, Inc.
    • American Gene Technologies International Inc.
    • Aprea AB
    • Cellceutix Corporation
    • Critical Outcome Technologies Inc.
    • Eleos Inc.
    • ORCA Therapeutics B.V.
    • OSE Pharma SA
    • PCI Biotech Holding ASA
    • Quark Pharmaceuticals, Inc.
    • Stemline Therapeutics, Inc.
    • Shenzen SiBiono GeneTech Co., Ltd.
    • SK Biopharmaceuticals Co., Ltd.
    • Tara Immuno-Oncology Therapeutics LLC
    • Z53 Therapeutics, LLC
  • 藥物簡介
    • Adxs-LmddA159
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • AG-1101
    • APR-017
    • APR-246
    • ATRN-502
    • cenersen sodium
    • contusugene ladenovec
    • COTI-2
    • D-12PGJ3
    • Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma
    • Gene Therapy to Activate p53 for Oncology
    • KM-3174
    • MHY-449
    • MJ-05
    • MX-225
    • N-2
    • Oncolytic Viruses to Activate p53 for Oncology
    • OSE-2101
    • p28
    • QPAL-1
    • QPI-1002
    • Recombinant Protein to Activate p53 for Oncology
    • SGT-53
    • SL-801
    • Small Molecule to Activate p53 for Cancer
    • Small Molecules to Activate p53 for Cancer and Viral Infections
    • Small Molecules to Activate p53 for Melanoma
    • Vaccine to Target Cellular Tumor Antigen p53 for Oncology
    • ZMC-1
  • 開發暫停的計劃
  • 開發中止的計劃
  • 值得注意的最新趨勢·新聞稿 (全10件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2021TDB

Summary

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 27 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The latest report Cellular Tumor Antigen p53 - Pipeline Review, H2 2019, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 7, 2, 7, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology and Toxicology which include indications Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Solid Tumor, Esophageal Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Pancreatic Cancer, Prostate Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bladder Cancer, Blood Cancer, Brain Cancer, Brain Tumor, Central Nervous System (CNS) Tumor, Cervical Cancer, Chemotherapy Effects, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Delayed Graft Function (DGF), Endometrial Cancer, Gastrointestinal Tumor, Gliosarcoma, Hepatic - Colorectal Metastasis, Hepatocellular Carcinoma, Leukemia, Li-Fraumeni Syndrome (LFS), Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma, Soft Tissue Sarcoma and Urinary Tract Cancer.

Furthermore, this report also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development
  • Actavalon Inc
  • ADRx Inc
  • Affina Biotechnologies Inc
  • Aprea Therapeutics AB
  • BlinkBio Inc
  • CanBas Co Ltd
  • Cotinga Pharmaceuticals Inc
  • Innovation Pharmaceuticals Inc
  • ISA Pharmaceuticals BV
  • LynkCell Inc
  • MultiVir Inc
  • ORCA Therapeutics BV
  • OSE Immunotherapeutics
  • Pharos I&BT Co Ltd
  • PMV Pharmaceuticals Inc
  • Quark Pharmaceuticals Inc
  • Shenzen SiBiono GeneTech Co Ltd
  • SynerGene Therapeutics Inc
  • Tara Immuno-Oncology Therapeutics LLC
  • Z53 Therapeutics LLC
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles
  • Adp-53DCV - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APR-246 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APR-548 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AU-14022 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • contusugene ladenovec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • COTI-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Actavalon Inc, H2 2019
  • Pipeline by ADRx Inc, H2 2019
  • Pipeline by Affina Biotechnologies Inc, H2 2019
  • Pipeline by Aprea Therapeutics AB, H2 2019
  • Pipeline by BlinkBio Inc, H2 2019
  • Pipeline by CanBas Co Ltd, H2 2019
  • Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
  • Pipeline by Innovation Pharmaceuticals Inc, H2 2019
  • Pipeline by ISA Pharmaceuticals BV, H2 2019
  • Pipeline by LynkCell Inc, H2 2019
  • Pipeline by MultiVir Inc, H2 2019
  • Pipeline by ORCA Therapeutics BV, H2 2019
  • Pipeline by OSE Immunotherapeutics, H2 2019
  • Pipeline by Pharos I&BT Co Ltd, H2 2019
  • Pipeline by PMV Pharmaceuticals Inc, H2 2019
  • Pipeline by Quark Pharmaceuticals Inc, H2 2019
  • Pipeline by Shenzen SiBiono GeneTech Co Ltd, H2 2019
  • Pipeline by SynerGene Therapeutics Inc, H2 2019
  • Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2019
  • Pipeline by Z53 Therapeutics LLC, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Dormant Products, H2 2019 (Contd..3), H2 2019
  • Dormant Products, H2 2019 (Contd..4), H2 2019
  • Dormant Products, H2 2019 (Contd..5), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top